Skip to main content
. Author manuscript; available in PMC: 2010 Nov 15.
Published in final edited form as: Clin Cancer Res. 2009 Nov 10;15(22):7036–7044. doi: 10.1158/1078-0432.CCR-09-1544

Figure 2.

Figure 2

Immune response rates by peptide (3-4 letter abbreviation), by HLA allele (A1, A2, or A3), and overall (12MP) for patients evaluated by direct ELIspot assay (A) or by Stimulated ELIspot assay (B). The proportion of patients meeting criteria for an ELIspot response are plotted for those in Groups A and C (no GMCSF — white bars) and those in Groups B and D (with GM-CSF — black bars). Response rates to each of the 12 HLA-class I peptides are shown, along with data for response rates to one or more peptides per HLA Class I allele (-A1, A2, or A3) or, for the direct ELIspot, to one or more of the 12MP.